Guangzhou Baiyun Womei Biotechnology, a joint venture between Guangzhou Baiyun Industrial Investment Group and Suzhou Womei Biology, completed its business registration on Aug 18.

This marks the establishment of the first public pilot-scale test platform in the niche field of "biomanufacturing + beauty, food, and agriculture" in South China, with plans afoot for it to become operational by the first quarter of 2027.

Facilities for the public pilot-scale test platform. [Photo/WeChat account: gz_baiyunfabu]

Located in the Baiyun Blue Bay Bio-Manufacturing Industrial Park, the platform features 10 specialized functional zones, equipped with multi-level fermentation, purification, drying, and high-end testing facilities. It will offer comprehensive services to academic teams, startups, technological SMEs, and traditional enterprises undergoing technological transformation.

With a planned maximum intelligent fermentation capacity of 5 metric tons, the platform aims to enhance the industrialization success rate of scientific research from 30 percent to 80 percent, addressing the challenges faced in biomanufacturing.

Baiyun Blue Bay Bio-Manufacturing Industrial Park. [Photo/WeChat account: gz_baiyunfabu]

Suzhou Womei Biology, one of only five enterprises nationwide to earn a five-star rating as a national biomanufacturing pilot-scale test platform, is a leader in national biomanufacturing core equipment development.